Log in

Relevant bibliographies by topics / Ovarian cancer, chemotherapy / Books

To see the other types of publications on this topic, follow the link: Ovarian cancer, chemotherapy.

Books on the topic 'Ovarian cancer, chemotherapy'

Author: Grafiati

Published: 24 April 2022

Last updated: 30 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 21 books for your research on the topic 'Ovarian cancer, chemotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Hess, Lisa M., David S. Alberts, and Mary C. Clouser. Intraperitoneal therapy for ovarian cancer. Springer, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Hyde, Susan Sturges. No more bad-hair days: A woman's journey through cancer, chemotherapy, and coping. Longstreet Press, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Excellence, National Institute for Clinical. Guidance on the use of paclitaxel in the treatment of ovarian cancer. National Institute for Clinical Excellence, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Graser, Angeline. Letters along my journey: My experience with cancer and chemotherapy. AuthorHouse, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

R, Lamonte Jean, ed. Aromatase inhibitors: Types, mode of action, and indications. Nova Science Publishers, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

R, Lamonte Jean, ed. Aromatase inhibitors: Types, mode of action, and indications. Nova Science Publishers, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

R, Lamonte Jean, ed. Aromatase inhibitors: Types, mode of action and indications. Nova Biomedical Books, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ozols, Robert F. High-dose Platinol (cisplatin for infection) in hypertonic saline. Bristol-Myers Oncology Division, 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Lamonte, Jean R. Aromatase inhibitors: Types, mode of action and indications. Nova Biomedical Books, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Malmström, Henric. Intraperitoneal chemotherapy of ovarian cancer. Linköping University, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Alberts, David, Lisa M. Hess, and Mary C. Clouser. Intraperitoneal Therapy for Ovarian Cancer. Springer, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

Gore, Martin, Stan Kaye, Hani Gabra, and Robert Brown. Emerging Therapeutic Targets in Ovarian Cancer. Springer, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

Alharbi, Yousef, Manish S. Patankar, and Rebecca J. Whelan. Antibody-Based Therapy for Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0006.

Full text

Abstract:

With their role in connecting disease-associated antigens to the cellular immune response, antibodies hold considerable promise as therapeutic agents. This chapter discusses three classes of therapeutic antibodies that have been developed for use in ovarian cancer therapy. The first includes antibodies selected against tumor-associated antigens such as MUC16/CA125, mesothelin, epithelial cell adhesion molecule, and folate receptor α‎. Antibodies in the second class target proteins such as CTLA-4 and PD1 that act as immune response checkpoint receptors. The third class of antibodies target secr

APA, Harvard, Vancouver, ISO, and other styles

14

Farghaly, Samir A. Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0005.

Full text

Abstract:

The standard management for epithelial ovarian cancer (EOC) is a combination of aggressive debulking surgery with residual tumor of less than 1 cm and platinum-based chemotherapy. However, a high percentage of patients experience disease recurrence. Extensive efforts to find new therapeutic options have been made, albeit cancer cells develop drug resistance and malignant progression occurs. Novel therapeutic strategies are needed to enhance progression-free survival and overall survival of patients with advanced EOC. Several preclinical and clinical studies investigated feasibility and efficac

APA, Harvard, Vancouver, ISO, and other styles

15

Oncology, Joint Council for Clinical. Current Role of Paclitaxel in the First-Line Chemotherapy of Ovarian Cancer (Improving Quality in Cancer Care). Royal College of Physicians of London, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

Solomon, H. C. Say No to Chemotherapy-Heal Cancer with Essential Oil&Diet : Prostate,Breast Cancer,Lung,Pancreatic,Skin Cancer,Ovarian,Colon,Cervical Cancer): Oils Healing Reference of 101 Disease. Independently Published, 2019.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

17

Cimpean, Anca Maria, Andreea Adriana Jitariu, and Marius Raica. Growth Factors and Their Corresponding Receptors as Targets for Ovarian Cancer Therapy. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0011.

Full text

Abstract:

Ovarian cancer remains one of the most aggressive and difficult to manage malignancies regarding evaluation and therapeutic options. The high mortality persists despite extensive research in the field. Current conventional chemotherapy does not improve disease-free survival and does not decrease recurrences amongst patients. This calls for a stringent reconsideration of the drugs selection, focused on the most targeted strategies and personalization of the therapy. Targeted agents against growth factors and their corresponding receptors are already approved as first- or second-line neoadjuvant

APA, Harvard, Vancouver, ISO, and other styles

18

(Editor), W. Jonat, M. Kaufmann (Editor), and K. Munk (Editor), eds. Hormone-Dependent Tumors: Basic Research and Clinical Studies : 9th International Expert Meeting of the Dr. Mildred Scheel Stiftung Fur Krebsforschung, ... 19 (Contributions to Oncology, Vol 50). S. Karger AG (Switzerland), 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Head and neck cancers. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689842.003.0021.

Full text

Abstract:

Outlines the epidemiology, aetiology, pathology and metastatic patterns of the common gynaecological diseases. Includes ovarian, uterine, cervical, vulval and trophoblastic cancers. Guides to diagnosis, staging and planning therapy. Outlines surgical, radiotherapy and chemotherapy options for both early stage and metastatic disease. Highlights the common dilemmas in planning therapy in women of child bearing potential and older women with concurrent illneses.

APA, Harvard, Vancouver, ISO, and other styles

20

Jōbō, Toshiko. Ransō no byōki: Gekkei no fuchō kara ransōgan made. 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

21

Cairns, John. Immunohistochemical staining of human breast and ovarian cancers for glutathione s-transferase and c-erbB-2 protein product: Correlation with clinical response to chemotherapy. 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!